Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin e Synthase-1 adversely affects the postoperative survival in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1167-1174

  Wu, Yu Chung ^a,b   Su, Li Jen ^c   Wang, Hao Wei ^a,b   Jeff Lin, Chien Fu ^d   Hsu, Wen Hu ^a,b   Chou, Teh Ying ^a,b   Huang, Chi Ying F ^b   Lu, Chia Li ^e   Hsueh, Chung Tsen ^f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f LOMA LINDA UNIVERSITY   (United States)

Author keywords

Cyclooxygenase 2; Microsomal prostaglandin E synthase 1; Non small cell lung cancer; Survival

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN E SYNTHASE 1;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MICROSOME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 77955094398     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e2f4f5     Document Type: Article

References (43)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
2. Khuder SA, Herial NA, Mutgi AB, et al. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005;127:748-754.
3. Van Dyke AL, Cote ML, Prysak G, et al. Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2008;17:148-157.
4. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56:387-437.
5. Watson DM, Kelly RW, Miller WR. Prostaglandins and prognosis in human breast cancer. Br J Cancer 1987;56:367-370.
6. Snyderman CH, Milanovich M, Wagner RL, et al. Prognostic significance of prostaglandin E2 production in fresh tissues of head and neck cancer patients. Head Neck 1995;17:108-113.
7. Sheng H, Shao J, Washington MK, et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276:18075-18081.
8. Kawamori T, Uchiya N, Sugimura T, et al. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003;24:985-990.
9. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89: 2637-2645.
10. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764.
11. Jakobsson PJ, Thoren S, Morgenstern R, et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, induc- ible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999;96:7220-7225.
12. Tanioka T, Nakatani Y, Semmyo N, et al. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000;275:32775-32782.
13. Murakami M, Nakashima K, Kamei D, et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003;278:37937-37947.
14. Murakami M, Nakatani Y, Tanioka T et al. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 2002;68-69:383-399.
15. Wang HW, Hsueh CT, Lin CF, et al. Clinical implications of microso- mal prostaglandin e synthase-1 overexpression in human non-small-cell lung cancer. Ann Surg Oncol 2006;13:1224-1234.
16. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001;7:2669-2674. (Pubitemid 32911370)
17. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-1610.
18. Travis WD, Sobin LH. Histological Typing of Lung and Pleural Tumours. New York: Springer, 1999.
19. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
20. Zhang F, Altorki NK, Wu YC, et al. Duodenal reflux induces cycloox- ygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001;121:1391-1399.
21. Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 1998;4:2201-2206.
22. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971-3976. (Pubitemid 34044615)
23. Blaine SA, Meyer AM, Hurteau G, et al. Targeted over-expression ofmPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice. Carcinogenesis 2005;26:209-217.
24. Martey CA, Pollock SJ, Turner CK, et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 2004;287:L981-L991.
25. Cui X, Yang SC, Sharma S, et al. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer. Biochem Biophys Res Commun 2006;343:995-1001.
26. Sanjana M, Akira M, Beamon A, et al. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 2006;208:356-363.
27. 2+-dependent phospholipase A2. J Neuro- chem 2004;91:1389-1397.
28. Grimmer C, Pfander D, Swoboda B, et al. Hypoxia-inducible factor 1alpha is involved in the prostaglandin metabolism of osteoarthritic cartilage through up-regulation of microsomal prostaglandin E synthase 1 in articular chondrocytes. Arthritis Rheum 2007;56:4084-4094.
29. Murakami M, Naraba H, Tanioka T, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275:32783-32792.
30. Yoshimoto A, Kasahara K, Kawashima A, et al. Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogen- esis, angiogenic factors and metastases. Oncol Rep 2005;13:1049-1057.
31. Winton T, Livingston R, Johnson D, et al, the National Cancer Institute of Canada Clinical Trials G and the National Cancer Institute of the United States Intergroup JBRTI. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352: 2589-2597. (Pubitemid 41007845)
32. Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
33. Chhatwani L, Cabebe E, Wakelee HA. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 2009;6:194-200.
34. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2004;92:131-139.
35. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-719. (Pubitemid 33040631)
36. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983.
37. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808.
38. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580.
39. Huang Y-T, Heist RS, Chirieac LR, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol 2009; 27:2660-2667.
40. Mascaux C, Martin B, Paesmans M, et al. Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 2006;95:139-145.
41. Altorki NK, Port JL, Zhang F, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005;11:4191-4197. (Pubitemid 40791585)
42. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo- oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-2650.
43. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B trial 30203. J Clin Oncol 2008;26:848-855.